Insider Trading May 11, 2026 04:28 PM

Vita Coco CCO Executes $599,270 Stock Sale Amid Strong Quarterly Performance

Charles van Es reduces direct holdings in COCO via Rule 10b5-1 plan as shares trade near 52-week highs.

By Leila Farooq COCO

Charles van Es, the Chief Commercial Officer of Vita Coco Company, Inc. (NASDAQ: COCO), recently completed a sale of common stock totaling $599,270. The transaction, which occurred on May 8, 2026, involved the disposal of 8,561 shares at a price point of $70.00 per share. This divestment was carried out under a pre-established Rule 10b5-1 trading plan. Following this sale, van Es retains a direct ownership stake of 67,130 shares in the company.

Vita Coco CCO Executes $599,270 Stock Sale Amid Strong Quarterly Performance
COCO

Key Points

  • Chief Commercial Officer Charles van Es sold 8,561 shares at $70.00 per share under a Rule 10b5-1 plan.
  • Vita Coco reported a significant Q1 2026 beat with $180 million in revenue and $0.50 EPS.
  • The stock is trading near its 52-week high of $72.98, though some assessments suggest it may be overvalued.

In a recent regulatory filing, it was disclosed that Charles van Es, serving as the Chief Commercial Officer for Vita Coco Company, Inc. (NASDAQ: COCO), has sold a portion of his equity in the firm. On May 8, 2026, van Es liquidated 8,561 shares of common stock at a valuation of $70.00 per share, resulting in a total transaction value of $599,270. This specific sale was executed in accordance with a Rule 10b5-1 trading plan.

Following the completion of this trade, Mr. van Es continues to hold 67,130 shares of Vita Coco common stock directly. The timing of this insider transaction is notable as the company's stock has been trading near its 52-week high of $72.98. At the time of reporting, COCO was valued at $72.46, which represents an increase from the $70.00 per share price at which the recent sale was conducted.


Equity Composition and Vesting Schedules

Beyond his direct holdings, Mr. van Es maintains several non-qualified stock options that grant him the right to purchase common stock. These options feature a range of exercise prices, starting as low as $10.178 and reaching up to $33.36. The expiration dates for these various option sets are scheduled between the years 2030 and 2035. While some of these options have achieved full vesting and are currently eligible for exercise, others remain subject to specific timelines.

The vesting structures include several distinct patterns:

  • Certain options vest through four equal annual installments, with schedules beginning on November 27, 2022, or August 15, 2025.
  • Options for 14,025 shares reached a vested status on February 20, 2026, following the fulfillment of designated performance conditions.
  • Additional options are slated to vest in four equal annual installments beginning on March 10, 2024, or March 4, 2025.
  • Other grants are scheduled to vest on each anniversary of the grant date, contingent upon the individual maintaining continuous service.

Financial Performance Context

The insider activity occurs against a backdrop of significant financial outperformance for The Vita Coco Company. During the first quarter of 2026, the company reported results that exceeded market expectations in both top and bottom-line metrics. Specifically, the company posted earnings per share (EPS) of $0.50, which surpassed the anticipated $0.32 by a margin of 56.25%.

Revenue for the first quarter also outperformed forecasts, reaching $180 million against a projected $147.39 million, representing a 22.12% beat. While these results signal robust financial health and an ability to outperform market expectations, they arrive as some analyses suggest the stock may be overvalued based on Fair Value assessments, noting a P/E ratio of 47.77.


Key Market Insights

  • Insider Sentiment and Valuation: The sale by a high-level executive through a Rule 10b5-1 plan provides a data point on internal liquidity, occurring while the stock trades near its annual highs. This impacts the consumer goods sector as investors weigh executive selling against strong earnings.
  • Earnings Momentum: The significant beat in both EPS and revenue highlights strong operational execution within the beverage/commodity space, impacting broader market perceptions of growth-oriented consumer stocks.

Risks and Uncertainties

  • Valuation Risk: With a P/E ratio of 47.77, there is an expressed concern regarding overvaluation relative to fair value assessments, which could impact volatility in the consumer staples sector.
  • Execution Dependency: The complexity of option vesting schedules and performance-based milestones highlights that future equity compensation remains tied to continuous service and specific company targets.

Risks

  • Potential stock overvaluation based on a P/E ratio of 47.77.
  • Reliance on continuous service and performance conditions for future equity vesting.

More from Insider Trading

Phillips 66 CFO Executes $5.1 Million Stock Sale Following Domestic Relations Order May 12, 2026 Texas Instruments Executive Executes $1.46 Million Stock Sale Amid Recent Price Surge May 12, 2026 Arteris CEO Charles Janac Executes $2.18 Million Stock Sale via Pre-Arranged Plan May 12, 2026 Bayview Legacy, LLC Reduces Position in Arteris, Inc. via Pre-Arranged Trading Plan May 12, 2026 Bridgewater Bancshares Director Mary Jayne Crocker Increases Position via Preferred Stock Purchase May 12, 2026